• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

October 19, 2021

Study: Exercise-Related Proteins May Suppress Prostate Cancer Tumor Growth

Author(s):

Aislinn Antrim, Managing Editor

Exercise can complement other treatments for prostate cancer, including androgen deprivation therapy, which can lead to significant reduction in lean mass and an increase in fat mass.

New research from Edith Cowan University suggests that proteins secreted after exercise could suppress tumor growth and actively fight cancerous cells.

Proteins called myokines are secreted by the muscles during exercise, according to the investigators. In a clinical trial, patients with obesity and prostate cancer underwent regular exercise training for 12 weeks and gave blood samples before and after the program. Researchers used these samples and applied them directly onto living prostate cancer cells.

“The patients’ level of anti-cancer myokines increased in the 3 months,” said study supervisor Robert Newton, PhD, a professor of exercise medicine at Edith Cowan University, in a press release. “When we took their pre-exercise blood and their post-exercise blood and placed it over living prostate cancer cells, we saw a significant suppression of the growth of those cells from the post-training blood. That’s quite substantial, indicating chronic exercise creates a cancer suppressive environment in the body.”

Although myokines could signal cancer cells to grow slower or stop growing completely, the researchers noted that they were unable to kill the cells by themselves. However, myokines can work with other cells in the blood to actively fight cancer.

“Myokines in and of themselves don’t signal the cells to die,” said research lead Jin-Soo Kim, a PhD candidate, in the press release. “But they do signal our immune cells—T cells—to attack and kill the cancer cells.”

Newton added that exercise can complement other treatments for prostate cancer, including androgen deprivation therapy (ADT), which can lead to significant reduction in lean mass and an increase in fat mass. This change can result in sarcopenic obesity, poorer health, and poorer cancer outcomes.

All study participants were undergoing ADT and were obese. According to the press release, the training program helped patients maintain lean mass while losing fat mass.

The study focused specifically on prostate cancer because it is the most common non-skin cancer among men and has a high number of patient fatalities, although the findings could have a wider impact. Further studies include a trial of patients with advanced-stage prostate cancer who are participating in a 6-month exercise program. Preliminary findings are encouraging, according to the study authors.

“These men have high disease burden, extensive treatment side-effects, and are very unwell, but they still can produce anti-cancer medicine from within,” Newton said in the press release. “It’s important as it may indicate why men even with advanced cancer, if they’re physically active, don’t succumb as quickly.”

REFERENCE

Cancer breakthrough: Exercise may stop disease in its tracks. News release. Edith Cowan University; October 5, 2021. Accessed October 11, 2021. https://www.ecu.edu.au/newsroom/articles/research/cancer-breakthrough-exercise-may-stop-disease-in-its-tracks

Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
Health care professional about to conduct a pap smear -- Image credit: Rabizo Anatolii | stock.adobe.com
May 9th 2025

FDA Approves Teal Wand, First At-Home Self-Collection Cervical Cancer Screening Device

Gillian McGovern, Associate Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
Teal ribbon for ovarian cancer awareness -- Image credit: Queenmoonlite Studio | stock.adobe.com
May 8th 2025

FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Microscopic view of abnormal plasma cell growth in bone marrow | Image Credit: © Diane - stock.adobe.com
May 8th 2025

FDA Grants Fast Track Designation to IBS 2001, An Investigational Trispecific Antibody for Multiple Myeloma

Alexandra Gerlach, Associate Editor
3D rendering of antibody-drug conjugates | Image Credit: © Love Employee - stock.adobe.com
May 8th 2025

Neoadjuvant Trastuzumab Deruxtecan Improves Pathologic Complete Response in Patients With HER2+ Early Breast Cancer

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Health care professional about to conduct a pap smear -- Image credit: Rabizo Anatolii | stock.adobe.com
May 9th 2025

FDA Approves Teal Wand, First At-Home Self-Collection Cervical Cancer Screening Device

Gillian McGovern, Associate Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
Teal ribbon for ovarian cancer awareness -- Image credit: Queenmoonlite Studio | stock.adobe.com
May 8th 2025

FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Microscopic view of abnormal plasma cell growth in bone marrow | Image Credit: © Diane - stock.adobe.com
May 8th 2025

FDA Grants Fast Track Designation to IBS 2001, An Investigational Trispecific Antibody for Multiple Myeloma

Alexandra Gerlach, Associate Editor
3D rendering of antibody-drug conjugates | Image Credit: © Love Employee - stock.adobe.com
May 8th 2025

Neoadjuvant Trastuzumab Deruxtecan Improves Pathologic Complete Response in Patients With HER2+ Early Breast Cancer

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.